Clinical Trials Browser

Hypersensitivity × 30 days × Clear all

Carcinoma, Carcinoma, Basal Cell, Eyelid Diseases, Eyelid Neoplasms, Hypersensitivity, Neoplasms, Glandular and Epithelial, Recurrence, Skin Diseases, Skin Neoplasms

NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Phase 2 Active not recruiting

237 enrolled

Myeloid

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

NCT07572162 2026-05-07

Post-market Safety Study of LUMISIGHT

Not yet recruiting

1,500 enrolled

Breast

Anaphylaxis, Breast Neoplasms, Drug Hypersensitivity, Hypersensitivity

NCT04996875 2026-05-05

APEX

Phase 2 Recruiting

140 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

Clinical Trials

dOCT-pBCC

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Post-market Safety Study of LUMISIGHT

APEX